In a head-to-head comparison, this refers to a ~ 26% relative risk reduction in stroke with non-selective versus selective SGLT2 inhibitors (HR, 0.74; 95% CI, 0.58–0.93). The gene discussed is SLC5A2; the disease is stroke disorder.